| 182.5 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 253.5 | 1-year : | 262.21 |
| Resists | First : | 217.04 | Second : | 224.5 |
| Pivot price | 215.12 |
|||
| Supports | First : | 204.97 | Second : | 170.54 |
| MAs | MA(5) : | 210.38 |
MA(20) : | 214.62 |
| MA(100) : | 212.39  |
MA(250) : | 195.07 |
|
| MACD | MACD : | -1.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 2.3 |
D(3) : | 14.1 |
| RSI | RSI(14): 38.7 |
|||
| 52-week | High : | 235.85 | Low : | 155.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALX ] has closed below the lower bollinger band by 0.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 4.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 206.8 - 208.79 | 208.79 - 209.99 |
| Low: | 200.67 - 203.33 | 203.33 - 204.94 |
| Close: | 202.43 - 206.73 | 206.73 - 209.33 |
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Mon, 15 Apr 2024
Fortress Biotech (FBIO) in Focus: Stock Moves 6.5% Higher - Yahoo Movies Canada
Sun, 14 Apr 2024
Is Alexion Pharmaceuticals, Inc.'s (NASDAQ:ALXN) High P/E Ratio A Problem For Investors? - Yahoo Movies Canada
Sat, 13 Apr 2024
Mersana Therapeutics (MRSN) Looks Good: Stock Adds 5.8% in Session - Yahoo Canada Shine On
Sat, 26 Mar 2022
Alexion Pharmaceuticals, Inc. Stock (ALXN) - Quote Nasdaq - Marketscreener.com
Wed, 26 May 2021
Alexion acquisition to be examined by U.K. regulators - Boston Business Journal - Boston Business Journal
Fri, 10 Jul 2020
Alexion Pharmaceuticals: Growth At A Reasonable Price (GARP) - Advisor Perspectives
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 58.3 (%) |
| Held by Institutions | 32.5 (%) |
| Shares Short | 107 (K) |
| Shares Short P.Month | 115 (K) |
| EPS | 19.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 46.52 |
| Profit Margin | 45.5 % |
| Operating Margin | 41.5 % |
| Return on Assets (ttm) | 3.7 % |
| Return on Equity (ttm) | 43.2 % |
| Qtrly Rev. Growth | 18.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 44.02 |
| EBITDA (p.s.) | 22.97 |
| Qtrly Earnings Growth | 23.5 % |
| Operating Cash Flow | 109 (M) |
| Levered Free Cash Flow | 54 (M) |
| PE Ratio | 10.28 |
| PEG Ratio | 0 |
| Price to Book value | 4.41 |
| Price to Sales | 4.66 |
| Price to Cash Flow | 9.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|